Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Valentina Norz & Steffen Rausch. (2021) Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?. Expert Review of Anticancer Therapy 21:2, pages 149-163.
Read now
Read now
C. M. Nijenhuis, J. H. M. Schellens & J. H. Beijnen. (2016) Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. Drug Metabolism Reviews 48:2, pages 266-280.
Read now
Read now
Elahe A Mostaghel. (2014) Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Management and Research 6, pages 39-51.
Read now
Read now
Articles from other publishers (46)
Eleanor Jing Yi Cheong, Sheng Yuan Chin, Zheng Wei Ng, Ting Jian Yap, Ervin Zhi Bin Cheong, Ziteng Wang & Eric Chun Yong Chan. (2023) Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement. Clinical Pharmacokinetics 62:9, pages 1243-1261.
Crossref
Crossref
Petr Buikin, Anna Vologzhanina, Roman Novikov, Pavel Dorovatovskii & Alexander Korlyukov. (2023) Abiraterone Acetate Complexes with Biometals: Synthesis, Characterization in Solid and Solution, and the Nature of Chemical Bonding. Pharmaceutics 15:9, pages 2180.
Crossref
Crossref
Wataru Fukuokaya, Keiichiro Mori, Takafumi Yanagisawa, Kohei Akazawa, Tatsuya Shimomura & Takahiro Kimura. (2023) Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials. Prostate Cancer and Prostatic Diseases.
Crossref
Crossref
Amr Elagamy, Laila K. Elghoneimy & Reem K. Arafa. 2023. Recent Developments in the Synthesis and Applications of Pyridines. Recent Developments in the Synthesis and Applications of Pyridines
375
410
.
Simon G. Wong & Shuguang Ma. 2023. Overcoming Obstacles in Drug Discovery and Development. Overcoming Obstacles in Drug Discovery and Development
137
174
.
Dorota Danielak, Tereza Krejčí & Josef Beránek. (2022) Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. European Journal of Pharmaceutical Sciences 176, pages 106254.
Crossref
Crossref
Yixin Hu, Jianyuan Wu, Xin Jiang, Guiying Chen, Yang Zhang, Luqin Si, Hongliang Jiang, Jiangeng Huang & Jianying Huang. (2022) Simultaneous determination of abiraterone and its five metabolites in human plasma by LC-MS/MS: Application to pharmacokinetic study in healthy Chinese subjects. Journal of Pharmaceutical and Biomedical Analysis 217, pages 114826.
Crossref
Crossref
Adili Keranmu, Fei-Ya Yang, Wasilijiang Wahafu, Su-Jun Han, Guo-Sheng Yang & Nian-Zeng Xing. (2022) Biotransformation of Abiraterone Into Five Characteristic Metabolites by the Rat Gut Microbiota and Liver Microsomes. Frontiers in Oncology 12.
Crossref
Crossref
Marlies Braeckmans, Patrick Augustijns, Raf Mols, Cécile Servais & Joachim Brouwers. (2022) Investigating the Mechanisms behind the Positive Food Effect of Abiraterone Acetate: In Vitro and Rat In Situ Studies. Pharmaceutics 14:5, pages 952.
Crossref
Crossref
Zeen Yang, Yinghong Yang, Mengyuan Xia, Wenjuan Dai, Bingqing Zhu & Xuefeng Mei. (2022) Improving the dissolution behaviors and bioavailability of abiraterone acetate via multicomponent crystal forms. International Journal of Pharmaceutics 614, pages 121460.
Crossref
Crossref
Yoshiyuki Sakai, Tatsuki Fukami, Mai Nagaoka, Keiya Hirosawa, Hiroyuki Ichida, Rei Sato, Kohei Suzuki, Masataka Nakano & Miki Nakajima. (2021) Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans. Life Sciences 284, pages 119896.
Crossref
Crossref
Urvi H. Gala, Dave A. Miller, Yongchao Su, Angela Spangenberg & Robert O. (Bill) WilliamsIIIIII. (2021) The effect of drug loading on the properties of abiraterone–hydroxypropyl beta cyclodextrin solid dispersions processed by solvent free KinetiSol® technology. European Journal of Pharmaceutics and Biopharmaceutics 165, pages 52-65.
Crossref
Crossref
Thaís Luise Dillenburg Weiss, Carolina Mesquita Furtado, Marina Venzon Antunes, Gustavo Gössling, Gilberto Schwartsmann, Rafael Linden & Simone Gasparin Verza. (2020) A quick UPLC–MS/MS method for therapeutic drug monitoring of abiraterone and delta(4)‐abiraterone in human plasma. Biomedical Chromatography 34:11.
Crossref
Crossref
Atul Bhatnagar, Matthew J. McKay, Malmaruha Arasaratnam, Megan Crumbaker, Howard Gurney & Mark P. Molloy. (2020) Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma. Journal of Mass Spectrometry 55:10.
Crossref
Crossref
Brendan A. Daisley, Ryan M. Chanyi, Kamilah Abdur-Rashid, Kait F. Al, Shaeley Gibbons, John A. Chmiel, Hannah Wilcox, Gregor Reid, Amanda Anderson, Malcolm Dewar, Shiva M. Nair, Joseph Chin & Jeremy P. Burton. (2020) Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nature Communications 11:1.
Crossref
Crossref
Valentina Norz, Laura Lawaczeck, Jens Bedke, Steffen Rausch & Arnulf Stenzl. (2020) Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial. Future Oncology 16:21, pages 1511-1524.
Crossref
Crossref
Tereza Boleslavská, Svatopluk Světlík, Pavel Žvátora, Jan Bosák, Ondřej Dammer, Josef Beránek, Petr Kozlík, Tomáš Křížek, Nikolina Kutinová Canová, Martin Šíma, Ondřej Slanař & František Štěpánek. (2020) Preclinical evaluation of new formulation concepts for abiraterone acetate bioavailability enhancement based on the inhibition of pH-induced precipitation. European Journal of Pharmaceutics and Biopharmaceutics 151, pages 81-90.
Crossref
Crossref
Hayley B. Schultz, Anthony D. Wignall, Nicky Thomas & Clive A. Prestidge. (2020) Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids. International Journal of Pharmaceutics 582, pages 119264.
Crossref
Crossref
Emeline Colomba, Grégoire Marret, Giulia Baciarello, Pernelle Lavaud, Christophe Massard, Yohann Loriot, Laurence Albiges, Edith Carton, Jérome Alexandre, Olivier Huillard, Stéphane Culine & Karim Fizazi. (2020) Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. European Journal of Cancer 129, pages 117-122.
Crossref
Crossref
Hayley B. Schultz, Tahlia R. Meola, Nicky Thomas & Clive A. Prestidge. (2020) Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. International Journal of Pharmaceutics 577, pages 119069.
Crossref
Crossref
Rami A. Masamrekh, Alexey V. Kuzikov, Yaraslau I. Haurychenka, Kirill A. Shcherbakov, Alexander V. Veselovsky, Dmitrii A. Filimonov, Alexander V. Dmitriev, Maria G. Zavialova, Andrei A. Gilep, Tatsiana V. Shkel, Natallia V. Strushkevich, Sergey A. Usanov, Alexander I. Archakov & Victoria V. Shumyantseva. (2019)
In vitro
interactions of abiraterone, erythromycin, and CYP3A4: implications for drug–drug interactions
. Fundamental & Clinical Pharmacology 34:1, pages 120-130.
Crossref
Crossref
Merel van Nuland, Julie M. Janssen, Bart van Hoek, Hilde Rosing, Jos H. Beijnen & André M. Bergman. (2019) Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. Clinical Genitourinary Cancer 17:5, pages e893-e896.
Crossref
Crossref
Atul Bhatnagar, Matthew J. McKay, Morten Thaysen-Andersen, Malmaruha Arasaratnam, Megan Crumbaker, Howard Gurney & Mark P. Molloy. (2019) Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients. Journal of Chromatography B 1126-1127, pages 121741.
Crossref
Crossref
Marie-Rose B. S. Crombag, Merel van Nuland, Andries M. Bergman, Hilde Rosing, Jan H. M. Schellens, Alwin D. R. Huitema & Jos H. Beijnen. (2018) Impact of age on exposure to oral antiandrogen therapies in clinical practice. Prostate Cancer and Prostatic Diseases 22:1, pages 168-175.
Crossref
Crossref
Tamás Solymosi, Ferenc Tóth, János Orosz, Orsolya Basa-Dénes, Réka Angi, Tamás Jordán, Zsolt Ötvös & Hristos Glavinas. (2018) Solubility Measurements at 296 and 310 K and Physicochemical Characterization of Abiraterone and Abiraterone Acetate. Journal of Chemical & Engineering Data.
Crossref
Crossref
Sisi Qin, Duan Liu, Manish Kohli, Liguo Wang, Peter T. Vedell, David W. Hillman, Nifang Niu, Jia Yu, Richard M. Weinshilboum & Liewei Wang. (2018) TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacology & Therapeutics 104:1, pages 201-210.
Crossref
Crossref
Merel van Nuland, Hilde Rosing, Jelle de Vries, Huib Ovaa, Jan H.M. Schellens & Jos H. Beijnen. (2017) An LC–MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma. Journal of Chromatography B 1068-1069, pages 119-124.
Crossref
Crossref
Guillemette E. Benoist, Eric van der Meulen, Floor J.E. Lubberman, Winald R. Gerritsen, Tineke J. Smilde, Jack A. Schalken, Jan H. Beumer, David M. Burger & Nielka P. van Erp. (2017) Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. Biomedical Chromatography 31:11, pages e3986.
Crossref
Crossref
Mohammad Alyamani, Zhenfei Li, Sunil K. Upadhyay, David J. Anderson, Richard J. Auchus & Nima Sharifi. (2017) Development and validation of a novel LC–MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column. The Journal of Steroid Biochemistry and Molecular Biology 172, pages 231-239.
Crossref
Crossref
Elahe A. Mostaghel, Eunpi Cho, Ailin Zhang, Mohammad Alyamani, Arja Kaipainen, Sean Green, Brett T. Marck, Nima Sharifi, Jonathan L. Wright, Roman Gulati, Lawrence D. True, Massimo Loda, Alvin M. Matsumoto, Daniel Tamae, Trevor N. Penning, Steven P. Balk, Phillip W. Kantoff, Peter S. Nelson, Mary-Ellen Taplin & R. Bruce Montgomery. (2017)
Association of Tissue Abiraterone Levels and
SLCO
Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer
. Clinical Cancer Research 23:16, pages 4592-4601.
Crossref
Crossref
Caly Chien, Michael Smith & Peter De Porre. (2017) Effect of food on abiraterone pharmacokinetics: a review. International Journal of Pharmacokinetics 2:3, pages 183-193.
Crossref
Crossref
Merel van Nuland, M. J. X. Hillebrand, H. Rosing, J. H. M. Schellens & J. H. Beijnen. (2017) Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma. Therapeutic Drug Monitoring 39:3, pages 243-251.
Crossref
Crossref
E. Carton, G. Noe, O. Huillard, L. Golmard, J. Giroux, A. Cessot, N.E.B. Saidu, M. Peyromaure, M. Zerbib, C. Narjoz, J. Guibourdenche, A. Thomas, M. Vidal, F. Goldwasser, B. Blanchet & J. Alexandre. (2017) Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. European Journal of Cancer 72, pages 54-61.
Crossref
Crossref
Guillemette E. Benoist, Rianne J. Hendriks, Peter F. A. Mulders, Winald R. Gerritsen, Diederik M. Somford, Jack A. Schalken, Inge M. van Oort, David M. Burger & Nielka P. van Erp. (2016) Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. Clinical Pharmacokinetics 55:11, pages 1369-1380.
Crossref
Crossref
J. Monbaliu, M. Gonzalez, A. Bernard, J. Jiao, C. Sensenhauser, J. Snoeys, H. Stieltjes, I. Wynant, J. W. Smit & C. Chien. (2016) In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. Drug Metabolism and Disposition 44:10, pages 1682-1691.
Crossref
Crossref
Sophie Geboers, Jef Stappaerts, Raf Mols, Jan Snoeys, Jan Tack, Pieter Annaert & Patrick Augustijns. (2016) The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man. Journal of Pharmaceutical Sciences 105:9, pages 2974-2981.
Crossref
Crossref
Tiphaine Belleville, Gaëlle Noé, Olivier Huillard, Audrey Thomas-Schoemann, Michel Vidal, François Goldwasser, Jerome Alexandre & Benoit Blanchet. (2015) A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. Journal of Chromatography B 989, pages 86-90.
Crossref
Crossref
Jef Stappaerts, Sophie Geboers, Jan Snoeys, Joachim Brouwers, Jan Tack, Pieter Annaert & Patrick Augustijns. (2015) Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics 90, pages 1-7.
Crossref
Crossref
Apexa Bernard, Nicole Vaccaro, Milin Acharya, James Jiao, Johan Monbaliu, Ronald De Vries, Hans Stieltjes, Margaret Yu, Namphuong Tran & Caly Chien. (2015) Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin. Clinical Pharmacology in Drug Development 4:1, pages 63-73.
Crossref
Crossref
Kim Stuyckens, Fred Saad, Xu Steven Xu, Charles J. Ryan, Matthew R. Smith, Thomas W. Griffin, Margaret K. Yu, An Vermeulen, Partha Nandy & Italo Poggesi. (2014) Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Naïve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacokinetics 53:12, pages 1149-1160.
Crossref
Crossref
Thomas Marbury, Eric Lawitz, Robert Stonerock, Martha Gonzalez, James Jiao, Jim Breeding, Christopher Haqq, Peter Verboven, Hans Stieltjes, Margaret Yu, Arturo Molina, Milin Acharya, Caly Chien & NamPhuong Tran. (2014) Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. The Journal of Clinical Pharmacology 54:7, pages 732-741.
Crossref
Crossref
Yu Gao, Jingwei Shao, Zhou Jiang, Jianzhong Chen, Songen Gu, Suhong Yu, Ke Zheng & Lee Jia. (2014) Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Discovery Today 19:3, pages 326-340.
Crossref
Crossref
Lina Yin & Qingzhong Hu. (2013) CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nature Reviews Urology 11:1, pages 32-42.
Crossref
Crossref
Sophie-Dorothee Clas, Rosa I. Sanchez & Rebecca Nofsinger. (2014) Chemistry-enabled drug delivery (prodrugs): recent progress and challenges. Drug Discovery Today 19:1, pages 79-87.
Crossref
Crossref
Isabel Heidegger, Petra Massoner, Iris E. Eder, Andreas Pircher, Renate Pichler, Friedrich Aigner, Jasmin Bektic, Wolfgang Horninger & Helmut Klocker. (2013) Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 138, pages 248-256.
Crossref
Crossref
Lina Yin, Qingzhong Hu & Rolf Hartmann. (2013) Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences 14:7, pages 13958-13978.
Crossref
Crossref